GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

Aerosol delivery devices are hand-held, portable drug delivery devices. They consist of suspension of solid or liquid particles in a carrier gas, which makes feasible for treatment of respiratory and ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...

After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review, data from the MATINEE study to support the regulatory ...